SAN DIEGO, CA--(Marketwire - Mar 26, 2013) - [ Santarus, Inc. ] (NASDAQ: [ SNTS ]) will hold an Investor and Analyst Day on Thursday, April 11, 2013 from 9:00 a.m. to 11:00 a.m. EDT (6:00 a.m. to 8:00 a.m. PDT) at the Millennium Broadway Hotel, 145 West 44^th Street, New York City. President and chief executive officer, Gerald T. Proehl, and other members of the senior management team will present an overview of the company's growth strategy, current commercial products and development pipeline to analysts and investors. In addition, a key opinion leader in gastroenterology will share his thoughts on ulcerative colitis and therapeutic perspectives. This event will be webcast live on Santarus' website at [ www.santarus.com ] beginning at 9:00 a.m. EDT. An archive of the webcast will be available shortly after conclusion of the event and can be viewed at the same link.

About Santarus

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. [ UCERIS™ ] (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and [ ZEGERID® ] (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists. [ GLUMETZA® ] (metformin hydrochloride extended release tablets) and [ CYCLOSET® ] (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes, and [ FENOGLIDE® ] (fenofibrate) tablets, which is indicated as an adjunct to diet to reduce high cholesterol, are promoted to endocrinologists and other physicians who treat patients with type 2 diabetes. Full prescribing and safety information for Santarus' products are available at [ www.santarus.com ]. 

Santarus' product development pipeline includes the investigational drug RUCONEST^® (recombinant human C1 esterase inhibitor) for treatment of acute attacks of hereditary angioedema. The company expects to submit a biologics license application (BLA) to the U.S. Food and Drug Administration for RUCONEST in the second quarter of 2013. Santarus is also developing rifamycin SV MMX^®, which is in Phase III clinical testing for treatment of travelers' diarrhea. In addition, the company has completed a Phase I clinical program with SAN-300, an investigational monoclonal antibody. More information about Santarus is available at [ www.santarus.com ].

Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans or objectives will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarus' business, including, without limitation: unexpected adverse side effects or inadequate therapeutic efficacy of Santarus' products and product candidates; the scope and validity of patent protection for Santarus' products and product candidates; and other difficulties or delays relating to the development, testing, manufacturing and marketing of, and obtaining and maintaining regulatory approvals for, Santarus' products and product candidates; and other risks detailed in Santarus' prior press releases as well as in prior public periodic filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Santarus^®, FENOGLIDE^®, UCERIS^™and ZEGERID^® are trademarks of Santarus, Inc. GLUMETZA^®is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc. CYCLOSET^®is a trademark of VeroScience LLC. MMX^®is a trademark of Cosmo Technologies Limited.
RUCONEST^®is a trademark of Pharming Group N.V.